Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03617198 · ClinicalTrials.gov registry record · Phase 1

CD4 CAR+ ZFN-modified T Cells in HIV Therapy

A Phase 1 study of HIV, sponsored by University of Pennsylvania.

Active
Registry status
Phase 1
Development phase
12
Enrollment target
1
Study location

NCT03617198: Active Phase 1 study of HIV, sponsored by University of Pennsylvania.

NCT03617198 is a Phase 1 study of HIV that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 12 participants, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03617198, a Phase 1 study of HIV, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This research study is being carried out to study a new way to possibly treat HIV. As part of this study, doctors will take some of your own white blood cells, called T-cells, and modify them so that they can identify and target your HIV cells. The purpose of the study is to evaluate the safety of these modified T cells and determine whether they have any effect on HIV infection.

Conditions Studied

HIV

Interventions

  • BIOLOGICAL CD4 CAR+CCR5 ZFN T-cells

Study Locations (1)

Pennsylvania

  • University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2019-07-31
Est. Completion 2027-12
Phase Phase 1
University of Pennsylvania

1,423 total trials

What the registry record for NCT03617198 still lists

NCT03617198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 440-participant average among 303 other HIV trials with a reported enrollment target (97% lower).

The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 1 intervention - of which CD4 CAR+CCR5 ZFN T-cells is the first listed.

NCT03617198 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03617198 about?

NCT03617198 is a clinical study titled "CD4 CAR+ ZFN-modified T Cells in HIV Therapy". This research study is being carried out to study a new way to possibly treat HIV. As part of this study, doctors will take some of your own white blood cells, called T-cells, and modify them so that they can identify and target your HIV cells. The purpose of the study is to evaluate the safety of t...

What is the current status of trial NCT03617198?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-07-31. Estimated completion is 2027-12.

What conditions does trial NCT03617198 study?

This clinical trial studies the following conditions: HIV.

What interventions are being tested in trial NCT03617198?

The interventions under investigation include: CD4 CAR+CCR5 ZFN T-cells (BIOLOGICAL).

Who is sponsoring clinical trial NCT03617198?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03617198 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03617198's enrollment target sits among peer trials

12 293rd of 303 higher than 7 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03617198, the US trial registry maintained by the National Library of Medicine. NCT03617198 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.